$Kinnate BioPharma Inc.(KNTE)$
A new pharmaceutical star or dust??[serious]
A biopharmaceutical company focused on the discovery and development of small molecules kinase inhibitors for difficult to treat, genomically defined cancers.
Listed on December 2020 only
Key ratio [Drowsy]
-basically the fundamental is still not solid with all the key ratio in bad numbers
-total debt to equity ratio 0.15
-negative fcf
Technical
-overall a down trend[Weak]
- short term wise rising trend with higher low value
-crossing above ema30 and 60 , approaching ema200[Put]
Next earning report in 15/8/2022
With all the past 6 quarters earning reports consecutively missed the estimate, will it continue the same or have a breakthrough?? [Doubt]
Surpassing the ema200 for first time ever since listed??[Thinking]
@Daily_Discussion@TigerPM@TigerStars@CaptainTiger
Comments